Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 5/20 | 0.47 |
| ▸ | ANPEP | P15144 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399455 | 0.89 | CARM1 (0.49) | MMP2ACECTSLCTSBCTSK | |
| SCHEMBL2525219 | 0.89 | CARM1 (0.49) | MMP2ACECTSLCTSBCTSK | |
| SCHEMBL2525161 | 0.88 | MMP2 (0.57) | MMP2AGTR2ACEANPEPCTSL | |
| SCHEMBL2525166 | 0.88 | MMP2 (0.57) | MMP2AGTR2ACEANPEPCTSL | |
| Danegaptide SCHEMBL29094836 | 0.87 | MMP2 (0.56) | MMP2AGTR2ACEANPEPCTSL | |
| Danegaptide SCHEMBL2399763 | 0.87 | MMP2 (0.56) | MMP2AGTR2ACEANPEPCTSL | |
| Danegaptide SCHEMBL25694359 | 0.87 | MMP2 (0.56) | MMP2AGTR2ACEANPEPCTSL | |
| Danegaptide SCHEMBL2399760 | 0.87 | MMP2 (0.56) | MMP2AGTR2ACEANPEPCTSL | |
| Danegaptide SCHEMBL20547963 | 0.87 | MMP2 (0.56) | MMP2AGTR2ACEANPEPCTSL | |
| Danegaptide SCHEMBL2521817 | 0.87 | MMP2 (0.56) | MMP2AGTR2ACEANPEPCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| US-8431540-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2012-09-27 | — | — | US | disclosed |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S and Wyeth | 2010-09-30 | — | — | US | disclosed |
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885AGTR2 715/4885ACE 863/4885 |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885AGTR2 715/4885ACE 863/4885 |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885AGTR2 715/4885ACE 863/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885AGTR2 715/4885ACE 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.